Open an account

60 Degrees Pharmaceuticals

SXTP · NASDAQ

$0.9222+$0.0229 (+2.55%)TodayMarket closed ·
Prev close $0.8993

SXTP analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $3.77 (+309.2% upside)

Low
$3.74
Now
$0.9222
High
$3.88

Upgrades and downgrades

The latest rating actions, newest first

SXTP analyst upgrades, downgrades and rating actions
FirmDateActionRating
Ascendiant CapitalMay 22, 2026MaintainsBuy
HC Wainwright & Co.May 20, 2026DowngradeBuy → Neutral
Ascendiant CapitalApr 9, 2026MaintainsBuy
HC Wainwright & Co.Jan 27, 2026MaintainsBuy
Ascendiant CapitalNov 28, 2025MaintainsBuy
HC Wainwright & Co.Nov 14, 2025InitiatesBuy

The case for and against

Updated Oct 21, 2026

Bull case

60 Degrees is supported by a clearer commercial and clinical path, as the February GoodRx launch and April Runway Health partnership broaden ARAKODA access while offering eligible patients savings of up to 30%. Its tafenoquine babesiosis program is an important value driver, with March results showing all three enrolled immunosuppressed patients were cured, while the emerging Australian Chestnut extract opportunity adds a non-Rx avenue through a potential dietary supplement. Financially, the company raised about $3.4 million net in Q1, ended with $3.3 million in cash, and faces an annual burn rate of roughly $8 million, implying additional equity financing will likely be needed to support execution.

Bear case

60 Degrees is facing a deteriorating financial profile, with Q1 FY26 product revenue falling to $162,000 and a net loss of $2.2 million, while operating expenses of $2.2 million outpaced limited sales and no forward guidance was provided. The company’s ARAKODA momentum weakened as US pharmacy/dispensary unit sales declined 19% year-over-year to 1,276 boxes, and returns tied to expiring lots highlighted fragile sell-through and poor revenue visibility. With only about $3.3 million in cash, rising burn, and uncertainty around funding, dilution, and clinical execution, the stock appears fundamentally pressured by an increasingly untenable balance sheet and limited near-term catalysts.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.